Inventor · disambiguated record
Nancy E. Stagliano
Also filed as: STAGLIANO NANCY · STAGLIANO NANCY E · Stagliano Nancy Elizabeth
41 granted patents·20 pending applications·1,260 citations·filing 2003–2025
99Inventor score
Files withCYTOMX THERAPEUTICS INC15BIOVERATIV USA INC11IPIERIAN INC11TRUE NORTH THERAPEUTICS INC8UNIV CALIFORNIA4
Top patents by PatentIndex Score
61 records- 0198US10875913B2Methods of treatment using activatable anti-EGFR antibodiesCYTOMX THERAPEUTICS INC·Filed 2018·Granted Dec 29, 2020·21 cites·40 claims
- 0298US10118961B2Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWVCYTOMX THERAPEUTICS INC·Filed 2016·Granted Nov 6, 2018·34 cites·13 claims
- 0398US10077300B2Activatable binding polypeptides and methods of identification and use thereofUNIV CALIFORNIA·Filed 2015·Granted Sep 18, 2018·42 cites·36 claims
- 0498US10059762B2Anti-EGFR activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 28, 2018·42 cites·41 claims
- 0598US9644016B2Soluble notch receptor proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted May 9, 2017·34 cites·28 claims
- 0698US8541203B2Activatable binding polypeptides and methods of identification and use thereofDAUGHERTY PATRICK SEAN·Filed 2012·Granted Sep 24, 2013·73 cites·41 claims
- 0798US8513390B2Modified antibody compositions, methods of making and using thereofSTAGLIANO NANCY E·Filed 2012·Granted Aug 20, 2013·111 cites·137 claims
- 0897US9777058B2Methods of treating a tauopathyIPIERIAN INC·Filed 2016·Granted Oct 3, 2017·12 cites·15 claims
- 0997US9447180B2Methods of treating a tauopathyIPIERIAN INC·Filed 2015·Granted Sep 20, 2016·15 cites·27 claims
- 1097US9169321B2Activatable binding polypeptides and methods of identification and use thereofUNIV CALIFORNIA·Filed 2013·Granted Oct 27, 2015·62 cites·41 claims
- 1197US9127053B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Sep 8, 2015·39 cites·33 claims
- 1297US9051367B2Methods of treating a tauopathyIPIERIAN INC·Filed 2014·Granted Jun 9, 2015·33 cites·22 claims
- 1397US8980271B2Methods of treating a tauopathyIPIERIAN INC·Filed 2014·Granted Mar 17, 2015·32 cites·21 claims
- 1497US8980270B2Methods of treating a tauopathyIPIERIAN INC·Filed 2014·Granted Mar 17, 2015·33 cites·50 claims
- 1597US8563269B2Modified antibody compositions, methods of making and using thereofSTAGLIANO NANCY E·Filed 2011·Granted Oct 22, 2013·119 cites·38 claims
- 1697US8529898B2Activatable binding polypeptides and methods of identification and use thereofDAUGHERTY PATRICK SEAN·Filed 2012·Granted Sep 10, 2013·64 cites·29 claims
- 1797US8399219B2Protease activatable interferon alpha proproteinSTAGLIANO NANCY E·Filed 2010·Granted Mar 19, 2013·46 cites·17 claims
- 1896US9453078B2Modified antibody compositions, methods of making and using thereofCYTOMX THERAPETUICS INC·Filed 2013·Granted Sep 27, 2016·64 cites·28 claims
- 1996US9206259B2Methods of inhibiting complement C4 activation with anti-complement C1S antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Dec 8, 2015·15 cites·13 claims
- 2096US8993266B2Proproteins activatable interferon alphaCYTOMX THERAPEUTICS INC·Filed 2012·Granted Mar 31, 2015·28 cites·14 claims
- 2196US8945562B2Anti-complement C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2013·Granted Feb 3, 2015·24 cites·47 claims
- 2296US8877197B2Anti-complement C1sTRUE NORTH THERAPEUTICS INC·Filed 2014·Granted Nov 4, 2014·22 cites·25 claims
- 2396US8518404B2Activatable binding polypeptides and methods of identification and use thereofDAUGHERTY PATRICK·Filed 2012·Granted Aug 27, 2013·105 cites·25 claims
- 2495US10513549B2Cleavage-activatable interferon-alpha proproteinCYTOMX THERAPEUTICS INC·Filed 2017·Granted Dec 24, 2019·14 cites·11 claims
- 2595US10301380B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2017·Granted May 28, 2019·17 cites·29 claims
- 2694US11028162B2Methods for manufacturing activatable binding polypeptides comprising matrix metalloprotease cleavable moietiesUNIV CALIFORNIA·Filed 2018·Granted Jun 8, 2021·6 cites·27 claims
- 2794US9562092B2Methods of inhibiting complement C4 activation with anti-complement C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Feb 7, 2017·10 cites·13 claims
- 2894US9512233B2Anti-complement C1s antibodies and methods of inhibiting complement C1s activityTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Dec 6, 2016·12 cites·41 claims
- 2994US9074004B2Methods of inhibiting activation of complement component C4 with anti-C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2014·Granted Jul 7, 2015·15 cites·13 claims
- 3094US9074003B2Methods of inhibiting activation of complement component C4 with anti-C1s antibodiesTRUE NORTH THERAPEUTICS INC·Filed 2014·Granted Jul 7, 2015·15 cites·30 claims
- 3193US12215169B2Anti-complement C1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2021·Granted Feb 4, 2025·1 cites·21 claims
- 3293US10450382B2Anti-complement C1s antibodiesBIOVERATIV USA INC·Filed 2016·Granted Oct 22, 2019·8 cites·9 claims
- 3393US9688748B2Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 27, 2017·11 cites·39 claims
- 3493US9567395B2Methods of treating a tauopathyIPIERIAN INC·Filed 2013·Granted Feb 14, 2017·16 cites·16 claims
- 3593US8926974B2Methods of treating a tauopathyIPIERIAN INC·Filed 2013·Granted Jan 6, 2015·45 cites·28 claims
- 3692US2025263503A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2024·Application pending·0 cites
- 3791US9562106B2Anti-complement C1s antibodies and methods of inhibiting complement C1s activityTRUE NORTH THERAPEUTICS INC·Filed 2015·Granted Feb 7, 2017·8 cites·31 claims
- 3890US10457745B2Anti-complement C1s antibodiesBIOVERATIV USA INC·Filed 2016·Granted Oct 29, 2019·6 cites·10 claims
- 3990US10040847B2Methods of treating a tauopathyIPIERIAN INC·Filed 2017·Granted Aug 7, 2018·6 cites·75 claims
- 4090US2024228603A1Modified antibody compositions, methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4185US2023183308A1Proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4283US12391750B2Anti-C1S antibodies and methods of use thereofBIOVERATIV USA INC·Filed 2023·Granted Aug 19, 2025·0 cites·16 claims
- 4382US12240917B2Anti-complement C1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2021·Granted Mar 4, 2025·0 cites·13 claims
- 4482US2025188192A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2025·Application pending·0 cites
- 4581US2023035290A1Proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4679US12209120B2Activatable anti-VEGF scFvUNIV CALIFORNIA·Filed 2021·Granted Jan 28, 2025·0 cites·3 claims
- 4776US2021284721A1Modified antibody compositions, methods of making and using thereofCYTOMX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4874US2020308243A1Proproteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4972US2020079875A1Anti-complement c1s antibodies and uses thereofBIOVERATIV USA INC·Filed 2019·Application pending·0 cites
- 5070US2025145696A1Methods for treating complement-mediated diseases and disordersBIOVERATIV USA INC·Filed 2024·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Nancy E. Stagliano files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →